Kiniksa Pharmaceuticals International, plc KNSA Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's total liabilities?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported total liabilities of $219.59M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's total liabilities changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's total liabilities increased by 54.8% year-over-year, from $141.84M to $219.59M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's total liabilities?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's total liabilities has grown at a 39.2% compound annual growth rate (CAGR), from $37.53M to $196.03M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.